A Case of Dasatinib-Induced Keratosis Pilaris

Main Article Content

Olivia Arriaza
Frank Winsett
Janice Wilson
Brent Kelly


keratosis pilaris, drug reaction, CML


Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) indicated for treatment of chronic myeloid leukemia (CML). Dasatinib targets several proteins specific to cancer pathogenesis such as Bcr-Abl, Src, c-kit and PDGFRb. Cutaneous reactions are a well-documented side effect of many TKIs, however, there are limited reports and characterization of dasatinib induced rash. We report a case of keratosis pilaris and follicular epithelial thinning in a 19-year-old patient one month after beginning dasatinib for treatment of CML. This report suggests a possible role of dasatinib in the induction of epithelial follicular instability via reduced Src activity and subsequent down regulation of EGFR.


1. Hořínková J, Šíma M, Slanař O. Pharmacokinetics of Dasatinib. Prague Med Rep. 2019;120(2-3):52-63. doi:10.14712/23362936.2019.10

2. Drucker AM, Wu S, Busam KJ, Berman E, Amitay-Laish I, Lacouture ME. Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: Meta-analysis and clinical characterization. Eur J Haematol. 2013;90(2):142-150. doi:10.1111/ejh.12052

3. Gambacorti-Passerini C, Aroldi A, Cordani N, Piazza R. Chronic myeloid leukemia: Second-line drugs of choice. Am J Hematol. 2016;91(1):67-75. doi:10.1002/ajh.24247

4. Cortes JE, Jones D, O’Brien S, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol. 2010;28(3):389-404. doi:10.1200/JCO.2009.25.4920

5. Patel AB, Solomon AR, Mauro MJ, Ehst BD. Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. Dermatology. 2016;232(1):122-125. doi:10.1159/000437383

6. Amitay-Laish I, Stemmer SM, Lacouture ME. Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. Dermatol Ther. 2011;24(4):386-395. doi:10.1111/j.1529-8019.2011.01431.x

7. Huang X, Patel S, Ahmed N, Seiter K, Liu D. Severe toxicity of skin rash, fever and diarrhea associated with imatinib: Case report and review of skin toxicities associated with tyrosine kinase inhibitors. Drug Des Devel Ther. 2008;(2):215-219. doi:10.2147/dddt.s3843

8. Tarantini F, Anelli L, Ingravallo G, et al. Skin lesions in chronic myeloid leukemia patients during dasatinib treatment. Cancer Manag Res. 2019;11:7991-7996. doi:10.2147/CMAR.S217872

9. Bergman JC, Ly TY, Keating MM, Hull PR. Recurrent and fixed neutrophilic dermatosis associated with dasatinib. J Cutan Med Surg. 2018;22(6):621-623. doi:10.1177/1203475418775663

10. Lin YC, Wu MH, Wei TT, et al. Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells. Neoplasia (United States). 2012;14(6):463-475. doi:10.1596/neo.12300

11. Ensslin CJ, Rosen AC, Wu S, Lacouture ME. Pruritus in patients treated with targeted cancer therapies: Systematic review and meta-analysis. J Am Acad Dermatol. 2013;69(5):708-720. doi:10.1016/j.jaad.2013.06.038

12. Chen Z, Oh D, Dubey AK, et al. EGFR family and Src family kinase interactions: mechanics matters? Curr Opin Cell Biol. 2018;51:97-102. doi:10.1016/j.ceb.2017.12.003